Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70)
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-018-0313-0
Abstract: IntroductionThis post hoc subanalysis of the randomized Japanese Primary Prevention Project investigated whether once-daily low-dose aspirin versus no aspirin reduced the risk of cardiovascular events (CVEs) in patients aged ≥ 70 years with atherosclerotic risk factors.MethodsPatients aged read more here.
Keywords: aspirin treated; risk; group; treated group ... See more keywords
Metabolome analysis of effect of aspirin on Drosophila lifespan extension
Sign Up to like & getrecommendations! Published in 2017 at "Experimental Gerontology"
DOI: 10.1016/j.exger.2017.04.010
Abstract: Abstract Effective approaches for drug development involve the repurposing of existing drugs which are already approved by the FDA. Aspirin has been shown to have many health benefits since its discovery as a nonsteroidal anti‐inflammatory… read more here.
Keywords: aspirin treated; metabolism; drosophila lifespan; analysis ... See more keywords
Apolipoprotein E*Ɛ2 carriers exhibit high aspirin-treated platelet reactivity and low cardiovascular risk during long-term aspirin treatment.
Sign Up to like & getrecommendations! Published in 2022 at "Age and ageing"
DOI: 10.1093/ageing/afac119
Abstract: OBJECTIVE Apolipoprotein E (APOE) loci, including rs429358 (Ɛ4) and rs7412 (Ɛ2), are involved in cardiovascular (CV) health. However, their effect on the CV-protective effect of aspirin remains unknown. METHODS A total of 515 aspirin-treated individuals… read more here.
Keywords: long term; aspirin treated; term aspirin; risk ... See more keywords